Latest Videos

Latest News

AI Biotech Secures Funding to Speed Up Stem Cell Therapy Development

AI Biotech Secures Funding to Speed Up Stem Cell Therapy Development

January 16th 2024

CellVoyant has raised £7.6 million in seed funding to speed up the development of novel cell therapies.

Pluri Launches New Cell Therapy CDMO Division

Pluri Launches New Cell Therapy CDMO Division

January 11th 2024

Pluri has launched PluriCDMO, a new contract development and manufacturing organization business that will offer cell therapy manufacturing services.

Clarivate Highlights 13 Potential Drugs to Watch in Latest Report

Clarivate Highlights 13 Potential Drugs to Watch in Latest Report

January 10th 2024

Clarivate's Drugs to Watch report highlights 13 potential blockbuster drugs and gamechangers set to launch in 2024.

Cherwell Joins AnalytiChem Group

Cherwell Joins AnalytiChem Group

January 10th 2024

Cherwell Laboratories’ cleanroom microbiology solutions will join AnalytiChem’s group of seven companies across Europe, North America, and Australia.

GSK to Acquire Aiolos Bio, Expands Respiratory Portfolio

GSK to Acquire Aiolos Bio, Expands Respiratory Portfolio

January 9th 2024

In a deal worth up to $1.4 billion, GSK aims to acquire Aiolos Bio and gain an expanded pipeline of biologic-based respiratory therapeutic candidates.

WuXi AppTec Expands Peptide and API Manufacturing

WuXi AppTec Expands Peptide and API Manufacturing

January 9th 2024

The expansion will boost solid-phase peptide synthesis total reactor volume to 32,000 L.

Boehringer Ingelheim and Ribo Partner on RNA-based Liver Disease Therapeutics

Boehringer Ingelheim and Ribo Partner on RNA-based Liver Disease Therapeutics

January 5th 2024

Under the collaboration, Boehringer Ingelheim and Ribo will develop RNA-based therapeutics to treat NASH/MASH.

Roche to Acquire Point-of-Care Technology from LumiraDx in $350 Million Deal

Roche to Acquire Point-of-Care Technology from LumiraDx in $350 Million Deal

January 4th 2024

Roche will acquire select parts of the LumiraDx group related to that company’s point-of-care technology, which integrates multiple tests on a single instrument.

AstraZeneca Poised to Acquire Cell Therapy Developer, Gracell, in Deal Valued at $1.2 Billion

AstraZeneca Poised to Acquire Cell Therapy Developer, Gracell, in Deal Valued at $1.2 Billion

January 4th 2024

AstraZeneca’s acquisition of Gracell includes a clinical-stage autologous cell therapy targeting hematologic malignancies and autoimmune diseases and a proprietary manufacturing platform.

QurAlis Opens European Headquarters in The Netherlands

QurAlis Opens European Headquarters in The Netherlands

January 4th 2024

The new Europe headquarters will be the hub for the company’s European operations, including production of product.